Overview Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) Status: Terminated Trial end date: 2010-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan. Phase: Phase 2 Details Lead Sponsor: James Graham Brown Cancer CenterUniversity of LouisvilleCollaborators: James Graham Brown Cancer CenterUniversity of LouisvilleTreatments: Rituximab